The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells

• Published in: Cellular signalling 2023-06, Vol.106, p.110634-110634, Article 110634
• Main Authors: Kollara, Alexandra, Burt, Brian D., Ringuette, Maurice J., Brown, Theodore J.
• Format: Article
• Language: English
• Subjects: Adaptor Proteins, Signal Transducing - metabolism; AKT; EGF; Epidermal Growth Factor - metabolism; ERBB2; ERK1/2; Female; Humans; Intracellular Signaling Peptides and Proteins - metabolism; Ovarian cancer; Ovarian Neoplasms - genetics; Ovarian Neoplasms - metabolism; Proto-Oncogene Proteins B-raf - genetics; Proto-Oncogene Proteins B-raf - metabolism; Proto-Oncogene Proteins c-akt - metabolism; Receptor, ErbB-2 - metabolism; Signal Transduction; VEPH1
• ISSN: 0898-6568; 1873-3913
• DOI: 10.1016/j.cellsig.2023.110634

Upregulation of ERBB2 and activating mutations in downstream KRAS/BRAF and PIK3CA are found in several ovarian cancer histotypes. ERBB2 enhances signaling by the ERBB family of EGF receptors, and contains docking positions for proteins that transduce signaling through multiple pathways. We identified the adaptor protein ventricular zone-expressed pleckstrin homology domain-containing protein 1 (VEPH1) as a potential interacting partner of ERBB2 in a screen of proteins co-immunoprecipitated with VEPH1. In this study, we confirm a VEPH1 - ERBB2 interaction by co-immunoprecipitation and biotin proximity labelling and show that VEPH1 interacts with the juxtamembrane-kinase domain of ERBB2. In SKOV3 ovarian cancer cells, which bear a PIK3CA mutation and ERBB2 overexpression, ectopic VEPH1 expression enhanced EGF activation of ERK1/2, and mTORC2 activation of AKT. In contrast, in ES2 ovarian cancer cells, which bear a BRAFV600E mutation with VEPH1 amplification but low ERBB2 expression, loss of VEPH1 expression enabled further activation of ERK1/2 by EGF and enhanced EGF activation of AKT. VEPH1 expression in SKOV3 cells enhanced EGF-induced cell migration consistent with increased Snail2 and decreased E-cadherin levels. In comparison, loss of VEPH1 expression in ES2 cells led to decreased cell motility independent of EGF treatment despite higher levels of N-cadherin and Snail2. Importantly, we found that loss of VEPH1 expression rendered ES2 cells less sensitive to BRAF and MEK inhibition. This study extends the range of adaptor function of VEPH1 to ERBB2, and indicates VEPH1 has differential effects on EGF signaling in ovarian cancer cells that may be influenced by driver gene mutations. •VEPH1 interacts with the juxtamembrane-kinase domain of ERBB2.•In SKOV3 cells overexpressing ERBB2, VEPH1 enhances EGF signaling and cell motility.•In BRAF mutated ES2 cells expressing low ERBB2, VEPH1 loss enhances EGF signaling.•VEPH1 loss in ES2 cells leads to decreased sensitivity to BRAF and MEK inhibition.